Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Non-cash Items (2022 - 2025)

Stoke Therapeutics (STOK) has 3 years of Non-cash Items data on record, last reported at $4.3 million in Q4 2024.

  • For Q4 2024, Non-cash Items fell 49.16% year-over-year to $4.3 million; the TTM value through Dec 2024 reached $4.3 million, down 49.16%, while the annual FY2024 figure was $4.3 million, 49.16% down from the prior year.
  • Non-cash Items reached $4.3 million in Q4 2024 per STOK's latest filing, down from $8.4 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $20.6 million in Q4 2022 and bottomed at $4.3 million in Q4 2024.
  • Average Non-cash Items over 3 years is $11.1 million, with a median of $8.4 million recorded in 2023.
  • Peak YoY movement for Non-cash Items: tumbled 59.05% in 2023, then tumbled 49.16% in 2024.
  • A 3-year view of Non-cash Items shows it stood at $20.6 million in 2022, then plummeted by 59.05% to $8.4 million in 2023, then crashed by 49.16% to $4.3 million in 2024.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $4.3 million in Q4 2024, $8.4 million in Q4 2023, and $20.6 million in Q4 2022.